Mörsdorf S, Köhler M, Leipnitz G, Wenzel E
Department of Clinical Haemostaseology and Transfusion Medicine, University of Saarland, Homburg/Saar, FRG.
Folia Haematol Int Mag Klin Morphol Blutforsch. 1988;115(4):503-7.
In our study, we wanted to evaluate the clinical effect of s.c. DDAVP on haemostasis in different kinds of bleeding disorders. A total of 109 patients was treated with DDAVP s.c. at a dose of 0.4 microgram/Kg body weight. An effect of DDAVP on F VIII modalities was found after s.c. injection in all patients, but in comparison to i.v. DDAVP, the effect seems to be somewhat less. From our data, the patients blood groups do not influence the amount of F VIII modalities. Furthermore, the s.c. injection of DDAVP was found to be effective in patients with disorders of primary haemostasis. A number of operations was performed under the use of s.c. DDAVP in 24 patients with different kinds of bleeding disorders, in none of them, bleeding complications occurred.
在我们的研究中,我们想要评估皮下注射去氨加压素(DDAVP)对不同类型出血性疾病止血的临床效果。共有109例患者接受了皮下注射DDAVP治疗,剂量为0.4微克/千克体重。皮下注射后,在所有患者中均发现DDAVP对F VIII模式有影响,但与静脉注射DDAVP相比,效果似乎略差。根据我们的数据,患者的血型不影响F VIII模式的量。此外,发现皮下注射DDAVP对原发性止血障碍患者有效。在24例患有不同类型出血性疾病的患者中,在使用皮下注射DDAVP的情况下进行了多次手术,其中无一例发生出血并发症。